FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. https://t.co/PrklmlcNRg
#OCENewsBurst
3 Strategies To Lead #Clinical#Research With Moral Integrity
“While data integrity is of utmost importance in clinical research, moral integrity is of greater importance.”
—Ravi Madan, MD, senior clinician, @theNCI @NCIResearchCtr
https://t.co/dDnjlcrcwU
Breaking news: @US_FDA approves darolutamide (Nubeqa) for metastatic castration sensitive #prostatecancer in combination with docetaxel based on the results of ph3 Arasens trial👇 @PCF_Science@OncoAlert@urotoday https://t.co/hsJ005pHjE
Check this out…find those with TMB 10+ ..ICI better than taxanes. ICIs vs Chemotherapy by TMB in Metastatic Castration-Resistant Prostate Cancer https://t.co/VIMJgGIvhx via @JAMANetworkOpen part of @JAMANetwork@DrWinstonTan1@RDroncaDr
While #BCR & #mCSPC#ProstateCancer exist on a Continuum, it is important to note that #ADT combo studies for mCSPC have all required positive findings on conventional imaging (CT & Tc99)
Thus no data actually supports ADT combinations based on PET findings alone
Just in: Propel trial of PARP inhibitor Olaparib + abiraterone in UNSELECTED pts in 1st line mCRPC #ProstateCancer meets its primary end point:rPFS Results bode well for ongoing trials with Enza+ Talazoparib and Abi+ Niraparib👇 https://t.co/ogHfMVd7ZV @OncoAlert@urotoday
Time to investigate targeted combinations in prostate cancer. Let’s take advantage of these alterations. #GUoncology#prostatecancer#individualizedmedicine
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castr | OTT @DovePress https://t.co/6HZHzktnbl
JUST Now, and a wow! Adjuvant nivolumab improves DFS as for high-Risk, Muscle-Invasive Urothelial Carcinoma (CheckMate-274). Big news for bladder cancer patients. Congrats @MattGalsky &colleagues! @OncoAlert . Melanoma, GEJ/E #ESMO20 and now UC for #nivo
https://t.co/KG5MOrHCXw
Happy to share our manuscript, demonstrating that co-targeting of PARP and PI3K signaling activates c-GAS/STING pathway within tumor-associated macrophages, thereby driving T cell recruitment/activation and tumor clearance in c-myc-driven prostate cancers.
https://t.co/zGPyZjMzy8
A long awaited study by Dr. Graff and colleagues. A phase II single-arm study of pembrolizumab with enzalutamide in mCRPC progressing on enzalutamide alone. Still waiting for the magic combination with #Immunotherapy for #ProstateCancer. https://t.co/IjJ1ggp50R
Overall Survival With the Addition of ADT or Brachytherapy Boost to External-Beam Radiotherapy in Patients With Localized Prostate Cancer https://t.co/fbHqIYS0Mb #pcsm#oncology#cancer#radonc
May 19: FDA approved olaparib (LYNPARZA, AstraZeneca) for deleterious/suspected deleterious germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer that has progressed following treatment with enzalutamide or abiraterone
#pcsm
https://t.co/faiRYdKkZe